{"filing":{"accession_number":"0001568651-26-000048","cik":"0001568651","ticker":"OSCR","company_name":"Oscar Health, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"oscr-20260529.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1568651/000156865126000048/oscr-20260529.htm"},"events":[{"id":2927,"run_id":2548,"accession_number":"0001568651-26-000048","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The disclosure centers on material changes to Mario Schlosser's compensatory arrangements under an amended and restated employment agreement, including reduction of base salary to $370,000, elimination of annual bonus eligibility, removal of long-term incentive/equity awards, and elimination of severance and healthcare benefits. While Schlosser's role transitions from President of Technology and CTO to Co-Founder \u0026 Advisor, the substantive focus of the filing is the restructuring of his compensation package, which would materially affect investor assessment of executive compensation and retention strategy.","company_name":"Oscar Health, Inc.","ticker":"OSCR","filing_date":"2026-06-02","items":[{"id":3734,"accession_number":"0001568651-26-000048","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on material changes to Mario Schlosser's compensatory arrangements under an amended and restated employment agreement, including reduction of base salary to $370,000, elimination of annual bonus eligibility, removal of long-term incentive/equity awards, and elimination of severance and healthcare benefits. While Schlosser's role transitions from President of Technology and CTO to Co-Founder \u0026 Advisor, the substantive focus of the filing is the restructuring of his compensation package, which would materially affect investor assessment of executive compensation and retention strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:43:24.838740+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3734,"accession_number":"0001568651-26-000048","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on material changes to Mario Schlosser's compensatory arrangements under an amended and restated employment agreement, including reduction of base salary to $370,000, elimination of annual bonus eligibility, removal of long-term incentive/equity awards, and elimination of severance and healthcare benefits. While Schlosser's role transitions from President of Technology and CTO to Co-Founder \u0026 Advisor, the substantive focus of the filing is the restructuring of his compensation package, which would materially affect investor assessment of executive compensation and retention strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:43:24.838740+00:00","company_name":"Oscar Health, Inc.","ticker":"OSCR","filing_date":"2026-06-02"}]}